

Application No. 09/859,503

APPENDIX F

Copies of information from the following web cites:

<http://home.attbi.com/~bkrentzman/misc/how.things.work/dna.transcription/cytokines.html>

<http://www.copewithcytokines.de/cope.cgi?001668>

<http://www.psoriasis.org/enbrel.approval.jan02.htm>

http://www.jnj.com/news_finance/402.htm

http://www.jnj.com/news/jnj_news/20020329_0810.htm



Enter a Key
Phrase and

Join Us

Members

Contact Us

Search

About Psoriasis

Psoriasis Therapies

Psoriasis Research

News & Events

Kids, Youth & Teens

Media Resources &
Links

Medical
Professionals

Home

News & Notices

New treatment approved for psoriatic arthritis

The U.S. Food and Drug Administration (FDA) has approved the drug etanercept (brand name Enbrel) for the treatment of psoriatic arthritis. Physicians can prescribe Enbrel by itself or in combination with methotrexate, another systemic treatment for the disease.

While other therapies are used to treat psoriatic arthritis, Enbrel is the first to receive specific FDA approval for "reducing the signs and symptoms" of active psoriatic arthritis. Psoriatic arthritis affects approximately 23 percent of people with psoriasis.

For more information about psoriatic arthritis and its treatments, request the NPF's free educational booklet *Psoriatic Arthritis*. We publish more than 30 free educational publications.

Also, the NPF recently conducted a nationwide survey to gather critical information about people who have psoriasis and psoriatic arthritis, the effect the diseases have on their lives and their experiences with treatment. Read this press release for more details.



Enbrel was originally approved for rheumatoid arthritis in 1998, and many physicians are familiar with prescribing it. Patients give themselves injections of the drug under the skin, usually twice per week.

How is it different?

Enbrel is one of many "biologic response modifiers" that have been in development and testing for psoriasis and psoriatic arthritis. This new class of drugs is genetically engineered to block key interactions between cells in the immune system involved in these diseases. Other treatments for psoriasis and psoriatic arthritis, particularly those used in moderate to severe cases, can have a widespread impact on the immune system.

Enbrel blocks the action of a cytokine (cellular "messenger") called tumor necrosis factor-alpha (TNF-alpha) by binding to the site that allows the cell to communicate with other cells. Normally, TNF-alpha plays an important role in our immune system by promoting inflammation to fight infections. For unknown reasons, TNF-alpha is overproduced in the synovial fluid (lubricating fluid of the joints) and tissue of joints as well as the skin of people with psoriatic arthritis and psoriasis.

Thus, TNF-alpha overstimulates inflammation, which leads to painful damage of the joints and connective tissue, as well the development of lesions on the skin.

How effective is Enbrel?

Enbrel is a maintenance drug. Once it is stopped, the symptoms of the disease return. Some patients will begin to experience improvement even after the first injection. A few patients begin to experience improvement even after the first injection.

injection. Many patients begin to experience improvements in the signs and symptoms of psoriatic arthritis after three to four weeks. By three months, a majority of patients in clinical trials experienced major improvement in both bone and skin disease.

In the last phase III trial before the drug was submitted to the FDA, 62 percent of patients on low doses of methotrexate who also took Enbrel achieved at least a 20 percent improvement in symptoms of psoriatic arthritis (tender and swollen joints, stiffness, pain, etc.) after three months.

Among patients who took Enbrel without methotrexate, 58 percent had at least a 20 percent improvement in their psoriatic arthritis. All patients received 25 milligrams of the drug twice a week and were compared to an equal number of patients who received no Enbrel.

Enbrel also appears to help improve the skin. After six months, 43 percent of patients with moderate to severe psoriasis achieved a 50 percent improvement in a typical lesion, and a 47 percent improvement in their psoriasis overall.

The trial included 205 patients at 17 clinics across the country.

What are the side effects?

In clinical trials, the principal side effects related to Enbrel were minor reactions at the site of injection (36 percent of patients). The injection site reactions have been reported to be like mosquito bites that tend to fade by themselves and are no reason to stop the medication.

Because Enbrel blocks the action of a cell (TNF-alpha) that normally plays an important role in the immune system, it is believed to affect a person's ability to fight infections. Physicians are encouraged to exercise caution when considering the use of Enbrel in patients with a history of recurring infections. However, in clinical trials, infectious events such as upper respiratory and urinary infections occurred with equal frequency between those taking Enbrel and those not, which is reassuring regarding the issue of predisposition to infection.

Recently, the FDA recommended that doctors test patients for tuberculosis (TB) before they take a drug similar to Enbrel called Remicade. Remicade is also an anti-TNF inhibitor, and it appears to contribute to the emergence of TB in patients who have a silent, or dormant, infection with TB. The same recommendation has not been made for Enbrel, but some rheumatologists nonetheless test any patient for dormant TB prior to prescribing anti-TNF therapy.

People with known multiple sclerosis should not take Enbrel. Since the drug was approved for rheumatoid arthritis, a handful of new or exacerbated multiple sclerosis cases has been seen. Physicians should advise their patients about this issue, but the risk is very small and in the great majority of patients outweighed by the potential benefits of the drug.

Based on all of the safety information available on Enbrel since the drug has been approved for rheumatoid arthritis, the FDA requires the warning label on the medication to state that there is a risk of serious, even life-threatening, infections in some people, especially if their immune system is already compromised. The drug may be temporarily discontinued in people who have active infections, such as lung infections or flu.

Unlike the situation with methotrexate patients, regular blood tests to determine whether Enbrel is harming the liver will not be required.

How do I get it?

Immunex is requiring patients to join an enrollment program to receive Enbrel, but has not stated how long patients must wait before receiving the drug. According to company spokesperson Robin Shapiro, part of the reason the program is in place is to help the company monitor demand for the drug.

Patients who call the enrollment program (1-888-4-ENBREL) are asked for their names, address and mailing information. The company sends a package of information, including a release form patients are required to get their physician to sign. Before patients are placed on the waiting list, they need to send the signed form back to the company, as well as documentation that their insurance company will cover the drug.

According to Immunex, approximately 3,000 people per month are being moved from the waiting list to the active list to begin receiving Enbrel. Company officials say they do not know how many people are now on the waiting list, but that since 1998, Enbrel has been prescribed to 120,000 people.

Depending on where the drug is purchased, Enbrel costs approximately \$12,000 per year.

Currently, Medicare does not cover prescription drugs, and so Enbrel is not covered. However, Immunex does report it has had great success working with people to get their private insurance companies to cover the treatment.

By calling the enrollment program number, patients can also talk to insurance specialists who can help walk them through the insurance process. The same number also puts patients in touch with nurses and allows them to order free needle disposal containers and sign up for prescription reminders, e-mail alerts and newsletters about Enbrel. The line is staffed Monday through Friday, from 9 a.m. to 9 p.m. EST.

*Article reviewed Jan. 9, 2002
First posted Jan. 16, 2002
Last updated Jan. 17, 2002*

Cytokines

Cytokine

Protein secreted by a cell that signals other cells in a paracrine fashion or even itself (autocrine). The various lymphokines, chemokines, interferons, colony-stimulating factors, and tumor necrosis factors are examples. [cytokine receptors]

Cytokines, unlike hormones, go to nearby cells, or even the cell that produced the signaling molecule, and work there. They usually do not pass into the blood. Hormones are created in special organs and pass into the blood to act at distant sites.

The term cytokine, or immunocytokines, was used initially to separate a group of immunomodulatory proteins, called also **immunotransmitters**, from other **Growth factors** that modulate the proliferation and bioactivities of non-immune cells. However, this terminology suggesting a clear-cut distinction cannot be maintained and may not be meaningful altogether. Some cytokines are produced by a rather limited number of different cell types while others are produced by almost the entire spectrum of known cell types.

The initial concept of "one producer cell -one cytokine -one target cell" has been falsified for almost every cytokine investigated more closely. A definition of these factors on the basis of their producer or target cells is therefore also problematic.

The same applies to classifications based upon identical or shared biological activities of cytokines especially with broad definitions (see, for example: BCDF (B-cell differentiation factors), BCGF (B-cell growth factors), Motogenic cytokines , Chemotactic cytokines (see: Chemokines), CSF (colony stimulating factors), angiogenesis factors, or TRF (T-cell replacing factors)) (for some personal views on aspects of nomenclature see also: Some personal remarks).

Designations such as HBGF (heparin-binding growth factors) take into account some biochemical shared by a variety of cytokines but are also problematic.

Today the term cytokine is used as a generic name for a diverse group of soluble proteins and peptides which act as humoral regulators at nano- to picomolar concentrations and which, either under normal or pathological conditions, modulate the functional activities of individual cells and tissues. These proteins also mediate interactions between cells directly and regulate processes taking place in the extracellular environment (for some mechanistic concepts underlying cytokine actions see also: autocrine , paracrine , juxtacrine , retrocrine). Many growth factors and cytokines act as cellular survival factors by preventing programmed cell death (see: Apoptosis).

In many respects the biological activities of cytokines

resemble those of classical hormones produced in specialized glandular tissues. Some cytokines also behave like classical hormones in that they act at a systemic level, affecting, for example, biological phenomena such as inflammation , systemic inflammatory response syndrome , and acute phase reaction , wound healing , and the neuroimmune network .

In general, cytokines act on a wider spectrum of target cells than hormones. Perhaps the major feature distinguishing cytokines from mediators regarded generally as hormones is the fact that, unlike hormones, cytokines are not produced by specialized cells which are organized in specialized glands, i. e. there is not a single organ source for these mediators. The fact that cytokines are secreted proteins also means that the sites of their expression does not necessarily predict the sites at which they exert their biological function.

Some cytokines have been found, upon determination of their primary structures, to be identical with classical enzymes (see, for example: ADF (adult T-cell leukemia-derived factor) , nm23 , PD-ECGF (platelet-derived endothelial cell growth factor) , neuroleukin). Cytokines normally do not possess enzymatic activities although there is a growing list of exceptions.

The biological activities of cytokines can be measured by a variety of Bioassays employing, among other

things, Factor-dependent cell lines , or by other assays using, for example, antibodies (see also: Cytokine assays , WHO cytokine standardization). RT-PCR quantitation of cytokines employs modern techniques of molecular biology and detects the presence of mRNA encoding specific cytokines.

In the more restricted sense cytokines comprise Interleukins , initially thought to be produced exclusively by leukocytes, Lymphokines , initially thought to be produced exclusively by lymphocytes, Monokines , initially thought to be produced exclusively by monocytes, interferons (see: IFN), initially thought to be involved in antiviral responses, colony stimulating factors (see: CSF), initially thought to support the growth of cells in semi-solid media (see also: Colony formation assay), Chemokines , thought to be involved in Chemotaxis , and a variety of other proteins.

The term **Type-1 cytokines** refers to cytokines produced by Th1 T-helper cells while **Type-2 cytokines** are those produced by Th2 T-helper cells. Type-1 cytokines include IL2 , IFN-gamma , IL12 and TNF-beta , while Type-2 cytokines include IL4 , IL5 , IL6 , IL10 , and IL13 .

It has been suggested that the generic term **Peptide regulatory factors** (abbrev. PRF) be used for all these factors to avoid the general difficulties with the nomenclature (see also: Some personal remarks). This term has the advantage that it includes also a

number of low molecular mass peptides which are generally not regarded as cytokines although they have many activities of cytokines. Some of these low molecular weight proteins and peptides have been referred to as **Minicytokines**.

Most cytokines are unrelated in terms of sequence although some can be grouped into families (see: Gene family ; see also: Cytokine receptor families) or are classified into categories according to the types of secondary and tertiary structure.

IFN-alpha , IFN-beta , IFN-omega , IL2 , IL3 , IL4 , IL5 , IL6 , IL7 , IL9 , G-CSF , M-CSF , GM-CSF , and PDGF , for example, have an alpha-spiral secondary structure. Beta-structural cytokines include IL1-alpha , IL1-beta , TNF-alpha , TNF-beta , and FGF . Composite structures (alpha +beta) are observed, among other things, with IL8 , IFN-gamma , IP-10 , PF4 , GRO , 9E3 . According to the type of tertiary structure, alpha-spiral proteins can be grouped further into IFN like and IL2 like families, and beta-structural proteins can be grouped into IL1 like and TNF like families. For other aspects of biochemistry see also: Recombinant cytokines , Muteins , Peptide mimetics .

Most cytokines are glycoproteins which are secreted by cells using classical secretory pathways (see also: signal sequence). Many genes encoding cytokines can give rise to a variety of variant forms of cytokines by means of alternative splicing, yielding

molecules with slightly different but biologically significant bioactivities. In many cases the expression patterns of different forms of cytokines or of members of a cytokine family are overlapping only partially, suggesting a specific role for each factor.

Membrane-bound forms have been described also for many cytokines, and some may be associated also with the extracellular matrix. It is likely that the switching between soluble and membrane forms of cytokines is an important regulatory event (see also: Autocrine, paracrine, juxtacrine, retrocrine). In some cases membrane forms of a cytokine have been found to be indispensable for normal development, with soluble forms being unable to entirely substitute for them.

Most cytokines are generally not stored inside cells (exceptions are, for example TGF-beta and PDGF which are stored in platelets). The expression of most cytokines is regulated tightly at practically all levels: these factors are usually produced only by cells after cell activation in response to an induction signal. Expression can be regulated at the level of transcription, translation, and protein synthesis (see also: gene expression; ARE (AU-rich element)). Normally, cytokines are expressed transiently only but constitutive expression has been observed also. The expression of many cytokines also seems to be regulated differentially, depending on cell type and developmental age. Secretion or release from producer cells is a regulated process. Once released,

their behaviour in the circulation may be regulated by soluble receptors and specific or unspecific binding proteins. Regulation also is at work at the receptor level on target cells and at the level of signaling pathways governing alterations in the behaviour of responder cells.

Most cytokines were detected initially in functional tests in vitro as biochemically undefined activities or as distinct factors with distinct biological activities. This also explains, at least in part, the plethora of different names for some of the cytokines. In many instances these activities were named after a particular biological activity observed in an in vitro assay (see also: [Bioassays](#) and [Cytokine assays](#) for alternatives) or after cells that were found to elaborate these factors (for techniques allowing identification of cytokine genes, cytokine receptor genes, and other relevant genes without prior knowledge of their activities see: [Gene library](#)). One should be aware of the fact that at this moment in time the relevance of many in vitro activities of cytokines to their endogenous functions within an intact organism is not clearly defined.

Almost all cytokines are pleiotropic effectors showing multiple biological activities. In addition, multiple cytokines often have overlapping activities and a single cell frequently interacts with multiple cytokines with seemingly identical responses (cross-talk). One of the consequences of this functional overlap is the observation that one factor may frequently

functionally replace another factor altogether or at least partially compensate for the lack of another factor. Since most cytokines have ubiquitous biological activities, their physiologic significance as normal regulators of physiology is often difficult to assess.

Studies of gene functions in experimental transgenic animals in which a cytokine gene has been functionally inactivated by gene targeting (see also: Knock-out) are of particular importance in research on cytokines because, unlike in vitro studies, they provide information about the true in vivo functions of a given cytokine by highlighting the effects of their absence. In many instances these studies have shown that null mutations of particular cytokine genes do not have the effects in vivo expected from their activities in vitro. If information about loss-of-function studies is available for a given cytokine or its receptor and if I had time to add the information it can be found as a special subentry (Transgenic/Knock-out/Antisense studies) for each particular cytokine.

Many cytokines show stimulating or inhibitory activities and may synergise or antagonize also the actions of other factors. A single cytokine may elicit reactions also under certain circumstances which are the reverse of those shown under other circumstances. The type, the duration, and also the extent of cellular activities induced by a particular cytokine can be influenced considerably by the

micro-environment of a cell, depending, for example, on the growth state of the cells (sparse or confluent), the type of neighboring cells, cytokine concentrations, the combination of other cytokines present at the same time, and even on the temporal sequence of several cytokines acting on the same cell. Under such circumstances combinatorial effects thus allow a single cytokine to transmit diverse signals to different subsets of cells.

The fact that every cell type may have different responses to the same growth factor can be explained, at least in part, by different spectrums of genes expressed in these cells and the availability and levels of various transcription factors that drive Gene expression. The responses elicited by cytokines are therefore contextual and the "informational content", i. e. the intrinsic activities of a given cytokine may vary with conditions. Although a variety of cytokines are known to share at least some biological effects the observations that single cells usually show different patterns of gene expression in response to different cytokines can be taken as evidence for the existence of cytokine receptor-specific signal transduction pathways. Shared and different transcriptional activators that transduce a signal from a cytokine receptor to a transcription regulatory element of DNA are involved in these processes (for some examples see: STAT proteins, Janus kinases, IRS).

It has been observed, for example, that bFGF is a

strong mitogen for fibroblasts at low concentrations and a chemoattractant at high concentrations (see also: Chemotaxis). bFGF has been shown also to be a biphasic regulator of human hepatoblastoma-derived HepG2 cells, depending upon concentration. The interferon IFN-gamma can stimulate the proliferation of B-cells prestimulated with Anti-IgM, and inhibits the activities of the same cells induced by IL4 . On the other hand, IL4 activates B-cells and promotes their proliferation while inhibiting the effects induced by IL2 in the same cells. The activity of at least two cytokines (IL1-alpha and IL1-beta) is regulated by an endogenous receptor antagonist, the IL1 receptor antagonist (see: IL1ra). Several cytokines, including TNF , IFN-gamma , IL2 and IL4 , are inhibited by soluble receptors (see also: Receptor shedding , Cytokine inhibitors , retrocrine). Several cytokines, including IL10 and TGF-beta , act to inhibit other cytokines.

The processes responsible for the regulation of cytokines are not well understood. Cells utilize distinct biochemical pathways converging on mediator release and these can be probed, among other things, by employing a variety of substances mimicking or inhibiting the actions of cytokines (see, for example: Bryostatins , Calcium ionophore , Genistein , H8 , Herbimycin A , K-252a , Lavendustin A , Phorbol esters , Okadaic acid , Staurosporine , Suramin , Tyrphostins , Vanadate).

Frequently one observes a hierarchical order of

cytokine actions with some early Cytokines preactivating cells so that they then can respond to late-acting cytokines (see also: [Cell activation](#)). Many cytokines induce the synthesis of novel [gene products](#) once they have bound to their respective receptors (see: [ERG](#) , [Early response gene](#)). Some of the novel products are themselves cytokines (see: [Chemokines](#) , for example). In addition, there are a variety of [biological response modifiers](#) that function as [Anti-cytokines](#) .

Cytokine mediators can be transported quickly to remote areas of a multicellular organism. They can address multiple target cells and can be degraded quickly. Concentration gradients can be used to elicit specific responses. These possibilities by far exceed the possibilities provided by mere cell-to-cell contacts within a multicellular organism. It can be assumed that cytokines play a pivotal role in all sorts of cell-to-cell communication processes although many of the mechanisms of their actions have not yet been elucidated in full detail.

A close examination of the physiological and pathological effects of the regulated or deregulated (see: [Transgenic animals](#)) expression of cytokines in complex organisms has shown that these mediators are involved in virtually all general systemic reactions of an organism (see also: [CytokineTopics](#)), including such important processes as the regulation of immune responses (see, for example: [BCDF](#) , B-cell growth and differentiation factors; [BCGF](#) , [B-cell](#)

growth factors ; TRF , T-cell replacing factors ; Isotype switching), inflammatory processes (see: Inflammation), hematopoiesis (see also: Hematopoietins), and wound healing .

Cytokines are important mediators involved in embryogenesis and organ development (see also: Angiogenesis) and their activities in these processes may differ from those observed postnatally. In addition they play a key role in neuroimmunological, neuroendocrinological, and neuroregulatory processes (see: Neuroimmune network). Cytokines are important positive or negative regulators of mitosis (see also: Cell cycle), differentiation, migration (see also: Chemotaxis , Chemokines), cell survival and cell death (see also: Apoptosis), and transformation (see also: Oncogene). It has been shown that a number of viral infectious agents exploit the cytokine repertoire of organisms to evade immune responses of the host. Virus-encoded factors (see also: Virulence Factors MiniCOPE Dictionary .) appear to affect the activities of cytokines in at least four different ways: by inhibiting the synthesis and release of cytokines from infected cells; by interfering with the interaction between cytokines and their receptors; by inhibiting signal transmission pathways of cytokines; and by synthesizing virus-encoded cytokines that antagonize the effects of host cytokines mediating antiviral processes (see: Viroceptor , Virokine). Bacteria and other micro-organisms also appear to produce cytokine-like

substances which they utilize to subvert host responses (see: Bacteriokine , Microkine).

Cytokines themselves rarely are related closely among each other in terms of primary sequences. Some appear to have some common three-dimensional features and some of them can be grouped into families. For example, the TNF ligand superfamily members (with the exception of LT-alpha) are type II membrane glycoproteins with homology to TNF in the extracellular domain (overall homologies, 20 percent. The HBNF family includes members of the group of fibroblast growth factors . Another group of diverse factors with conserved sequence features are the Chemokines . The analysis of crystal structures of several cytokines with very little sequence homology has revealed a common overall topology that is not deducible from sequence comparisons (see: Cystine knot growth factor family).

The biological activities of cytokines are mediated by specific membrane receptors which can be expressed on virtually all cell types known. Their expression is also subject to several regulatory mechanisms (see: Receptor transmodulation) although some receptors are expressed also constitutively.

Cytokine receptor proteins have been shown to share a number of characteristics. Many receptors are members of cytokine receptor families . Many receptors are multi-subunit structures that bind

ligands and at the same time possess functions as signal transducers due to their intrinsic tyrosine kinase activity (see also: Autophosphorylation ; see also: PTK ; protein tyrosine kinase). Many receptors often share common signal transducing receptor components in the same family (see also: Cytokine receptor families), which explains, at least in part, the functional redundancy of cytokines. It is the cross-communication between different signaling systems that eventually allows the integration of a great diversity of stimuli, which a cell can be subjected to under varying physiological situations. This and the ubiquitous cellular distribution of certain cytokine receptors has hampered attempts to define critical responsive cell populations and the physiologically important cell-specific functions of cytokines in vivo. Many receptors are associated with special signal transducing proteins in the interior of the cell (see, for example Janus kinases , STAT proteins). Some receptors may bind more than one cytokine. Several cytokine receptors have been shown to be converted into soluble binding proteins that regulate ligand access to the cell by specific proteolytic cleavage of receptor ectodomains.

The many specific activities of individual cytokines have been the basis for current concepts of therapeutical intervention, in particular of the treatment of hematopoietic malfunctions and tumor therapy. Applications involve the support of chemo- and radiotherapy, bone marrow transplantation, and

general immunostimulation (see also: Adoptive immunotherapy , LAK cells , TIL , Cytokine gene transfer , Cytokine fusion toxins).

Although some recombinant cytokines are now in clinical use, and attempts are made to develop hybrid molecules from known cytokines (see: Mutagens) which possess the advantages of the respective factors, but not their disadvantages, one must be aware of the fact that current knowledge is still limited. Cytokines are powerful two-edged weapons that can trigger a cascade of reactions, and may show activities that often go beyond the single highly specific property which it is hoped they possess. New factors are being discovered constantly and they extend our knowledge about the Cytokine network .

Nevertheless it can be stated that our new (and growing) understanding of the biological mechanisms governing cytokine actions are an important contribution to medical knowledge. The biochemistry and molecular biology of cytokine actions explain some well-known and sometimes also some of the more obscure clinical aspects of diseases. Knowledge that cytokines create regulatory hierarchies and provide independent and/or interrelated regulatory mechanisms that can confer distinct and interactive developmental functions lays a solid, albeit rather complicated foundation, for current and future clinical experiences.

date of last revision: March 2002

References: Balkwill FR and Balkwill F (editors)
Cytokine Molecular Biology: A Practical Approach,
Oxford University Press (2000);

Balkwill FR (editor) Cytokine Cell Biology: A
Practical Approach, 3rd edition, Oxford University
Press (2001);

Callard RE (editor) Cytokines and B lymphocytes.
Academic Press, London, 1991;

Dinarello CA et al (editors) The physiological and
pathological effects of cytokines. Liss, New York,
1990;

Habenicht A (editor) Growth factors, differentiation
factors, and cytokines, Springer, Berlin 1990;

Nilsen-Hamilton M (editor) Growth factors and
development. (Current Topics in Developmental
Biology, Vol. 24, Academic Press 1990;

Oppenheim J Immunophysiology: The Role of Cells
and Cytokines in Immunity and Inflammation, Oxford
University Press (1991) ;

Oppenheim J et al (editors) Cytokine Reference: A
Compendium of Cytokines and Other Mediators of
Host Defense, Academic Press (2000);

Ransohoff RM (Editor), Cytokines and the CNS,
CRC Press (1996);

Westwick SL et al (eds) Chemotactic cytokines.
Plenum Press, New York 1991)



Welcome to Horst Ibelgauf's
COPE
Cytokines Online Pathfinder Encyclopaedia


Version 8.7 (April 2002)

8,700+ entries; 18,000+ cited references; 68,000+ internal hyperlinks

including fully integrated MiniCOPE Dictionaries on Apoptosis, Cell lines, Chemokines, CytokineTopics, Hematology, Metalloproteinases Virokines, Viroceptors, Virulence Factors

Please keep COPE a free service! Place a banner ad.

upcoming event:



[A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#)
Structure of COPE | Browse contents, new entries, subdictionaries
Awards, Recognition, and Server statistics

Created, developed, and maintained by Horst Ibelgauf
Gene Center, Ludwig-Maximilians-Universität, München, Germany
Contact information

C opyright (C) 1997-2002 by H orst Ibelgauf's

cope.cgi version 0.014, revision April 8, 2002. (c) JI. Powered by Perl 5.00502

Horst Ibelgafts' COPE: Cytokines Online Pathfinder Encyclopaedia

COPE Philippine Universities Library Help Initiative



+ Antisense and Nucleic Acid Drug Development + Cloning + Cytokine + Cytokine and Growth Factor Reviews + DNA and Cell Biology + EMBO Journal + European Cytokine Network + Genetic Engineering News + Glycobiology + Human Molecular Genetics + Hybridoma + Immunology Today + International Immunology + Journal of Computational Biology + Journal of Immunological Methods + Journal of Interferon & Cytokine Research + Journal of the National Cancer Institute + Molecular Medicine Today + Nucleic Acids Research + Nucleic Acids Symposium Series + Protein Engineering + Trends in Biochemical Sciences + Trends in Cell Biology + Trends in Microbiology + Viral Immunology + Your Journal +

	sorry, this space is booked out	sorry, this space is booked out
Cytokine and Beyond March 27-28, 2003 San Diego		
COPE Homepage	Previous entry: chemokine-like factor 1	Next entry: Chemokinesis
		Random entry: IL6RE

Chemokines

New generic name given to a family of pro-inflammatory activation-inducible cytokines (see also: [Cell activation](#)) previously referred to as members of **SIS family of cytokines**, **SIG family of cytokines**, **SCY family of cytokines**, **Platelet factor-4 superfamily** or **Interkrines** (see also: [Gene family](#)). These proteins are mainly chemotactic for different cell types (hence the name, which is derived from (chemo)tactic cyto(kines); see also: [Chemotaxis](#)).

Chemokines have molecular masses of 8-10 kDa and show approximately 20-50 percent sequence homology among each other at the protein level. The proteins also share common gene structures and tertiary structures. All Chemokines possess a number of conserved cysteine residues involved in intramolecular disulfide bond formation.

According to the chromosomal locations of individual genes two different subfamilies of chemokines are distinguished. Members of the **Alpha-Chemokines** are referred to also as the **4q chemokine family** because the genes encoding members of this family map to human chromosome 4q12-21. The first two cysteine residues of members of this family are separated by a single amino acids and these proteins, therefore, are called also **CXC-Chemokines** . For a new systematic nomenclature of this group see also [SCY family of cytokines](#) . Some members of the subgroup of the human **CXC-Chemokines** are defined by the conserved **ELR sequence motif** (glutamic acid-

leucine-arginine) immediately preceding the first cysteine residue near the amino-terminal end. Chemokines with an ELR sequence motif have been found to chemoattract and activate primarily neutrophils. Chemokines without the ELR sequence motif appear to chemoattract and activate monocytes, dendritic cells, T-cells, NK-cells, B-lymphocytes, basophils, and eosinophils.

Members of the Beta-Chemokines or 17q chemokine family map to human chromosome 17q11-32 (murine chromosome11). The first two cysteine residues are adjacent and, therefore, these proteins are called also **CC-Chemokines** (for a new sytematic nomenclature of this group see also SCY family of cytokines). Some of the Beta-Chemokines contain two additional conserved cysteine residues and sometimes the term **C6-beta-Chemokines** is used for this subgroup.

ENA78	AGPAAAYLRELRCVCLQT - TQGVHPKMI SHLQVFAI GPOCSKVEVVA SLKH - GKEICLDP EAPFLKKVIQKILDGGNKEN
GCP-2	GPVSAVLTTEL RDTCLRYTLR. . .
GRO α	ASVAT EL RCQC LQT - LOGIHPKNI QSVNV KSPGP HCAQTEVIATL KH - GRKACL NPASPIVKKI I EKMLN SSKSH
GRO β	APLAT EL RCQC LQT - LOGIHLKNI QSVNV KSPGP HCAQTEVIATL KH - GRKACL NPASPMVKI I EKMLKNGKSH
GRO γ	ASVYTEL RCQC LQT - LOGIHLKNI QSVNV RSPGP HCAQTEVIATL KH - GRKACL NPASPMVKI I EKILNKGSTH
L8	AVLPRSAKEL RCQC IKTYSKP FHPKFI KELRY IESGPHCANTEIIVKL SD - GRELCLDP KENWVQRVV EKFLKRAENS
IP10	YPLSRTV RCTCISISNQPVNPRSL EKLEI IPA SQFCPRVEIIATMKKKGKGRCL NPE SKAIKNLL KAVSKEMSKRSP
NAP-2	AELRCMCIKT - TSGIHPKNI QSLV IGKGT HDNQVEVIATL KD - GRKICLDP DAPRIKKIVQKLAGDESAD
PF4	EA EEDGDLOC LCVKT - TSQVRPRHIT SLEVIKAGPHD PTAQLIATLKH - GRKICLQLQAPLYKKI IKKLL ES
HC 14	QPDVSI PITCCF NVI NRKIP IORLESY - TRI THIQCPKEAVI FK - TKRGKEVCADP KE RNV RDSMIKH LQGI FQNL KP
B09	SKSMQVPFS - RCCFSFAEQEI PLRAI LCV - - RNTSSICSN EGLIFK - LKRGKEACAL DT VGVVQRHRIQML RHCPSKRK
MCP-1	QPDAI NAPTCCY NFN RKISYQRLA SY - RRTTSSKCPKEAVI FK - TIYAKEICADP KIKWQDSMDHL DQGTQTPKT
MCP-3	QPVGI HTSTTCCYRFI NKKIP KDRLESY - RRTTSSHC PREAVI FK - TKLQKEICADPTQ KIWQDFMKH LDKGTQTPKL
MIP-1α	ASLAA DTPTACCF SYT SRQIPQNF IADY - - FETSSQC SKPGVI FL - TKRSRQVCADP SE EWQKYVSDLELSA
MIP-1β	APMGS DPTACCF SYTARKLP RNFFV DY - - YETSSLC SQPAVVFQ - TKRSKQVCADP SE SWQEVVYDLELN
RANTES	SPYSSDT - TPCCFAYIARPLPRAHIKEY - - FYTSGKCSNP AVVFV - TRKNRQVCANPEKIKW REYINSLEMS

Structure of some selected chemokines .

Alignment of some chemokine sequences showing the typical arrangement of cysteine residues in C-X-C (top) and CC (bottom) chemokines. Cysteine residues are shown in yellow. The ELR (Glu-Leu-Arg) sequence (red) is common to all Chemokines that activate neutrophil leukocytes.

The **C-Chemokines** or **Gamma-Chemokines** differ from the other chemokines by the absence of a cysteine residue. Members of the small group of chemokines with a **CXXXC cysteine signature motif** are referred to as **Delta-Chemokines** or **CX3C-Chemokines** or **CXXXC-Chemokines**). These proteins are type-1 transmembrane glycoproteins with the chemokine domain resting on top of an extended mucin-like stalk. A soluble form of the chemokine moiety can be released from its transmembrane anchor by extracellular cleavage.

The existence of clearly defined subgroups of chemokines on the basis of structural and functional properties illustrates the importance of

chemoattractant diversity in the regulation of leukocyte movement through the body.

Overview: the members of the four major classes of chemokines				
	C	CC	CXC	CX3C
		<u>6CKine</u> <u>464.1</u> <u>744.1</u>	<u>3-10C</u> <u>9E3</u>	
A	<u>ATAC</u>	<u>ABCD-1</u> <u>ABCD-2</u> <u>ACT-2</u> <u>ALP</u> <u>AMAC-1</u>	<u>AMCF-1</u> <u>AMCF-2</u> <u>AIF</u> <u>ANAP</u> <u>Angie</u> <u>Angie-2</u>	<u>ABCD-3</u>
B			<u>beta-R1</u> <u>Beta-Thromboglobulin</u> <u>BCA-1</u> <u>BLC</u> <u>blr-1 ligand</u> <u>BMAC</u> <u>bolekine</u> <u>BRAK</u>	
C		<u>C10</u> <u>CCF18</u> <u>CCK1</u> <u>CCL1</u> <u>CCL2</u> <u>CCL3</u> <u>CCL4</u> <u>CCL5</u> <u>CCL6</u> <u>CCL7</u> <u>CCL8</u> <u>CCL9</u> <u>CCL10</u> <u>CCL11</u> <u>CCL12</u> <u>CCL13</u> <u>CCL14</u> <u>CCL15</u> <u>CCL16</u> <u>CCL17</u>	<u>C7</u> <u>cCAF</u> <u>CEF-4</u> <u>CINC</u> <u>CINC-2-alpha</u> <u>CINC-2-beta</u> <u>CINC-2-beta-like</u> <u>CKA-3</u> <u>CRG-2</u> <u>CRG-10</u> <u>CTAP-3</u> <u>CXCL1</u> <u>CXCL2</u> <u>CXCL3</u> <u>CXCL4</u> <u>CXCL5</u> <u>CXCL6</u> <u>CXCL7</u> <u>CXCL8</u> <u>CXCL9</u> <u>CXCL10</u>	

		<u>CCL18</u> <u>CCL19</u> <u>CCL20</u> <u>CCL21</u> <u>CCL22</u> <u>CCL23</u> <u>CCL24</u> <u>CCL25</u> <u>CCL26</u> <u>CCL27</u> <u>CCL28</u> <u>Ck-beta-1</u> <u>Ck-beta-4</u> <u>Ck-beta-6</u> <u>Ck-beta-7</u> <u>Ck-beta-8</u> <u>Ck-beta-8-1 Ck-beta-9</u> <u>Ck-beta-10</u> <u>Ck-beta-11</u> <u>Ck-beta-12</u> <u>Ck-beta-15</u> <u>CTACK</u>	<u>CXCL11</u> <u>CXCL12</u> <u>CXCL13</u> <u>CXCL14</u> <u>CXCL15</u> <u>CXCL16</u>	
D		<u>DC/B-Ck</u> <u>DC-CK1</u>	<u>DNA binding protein</u>	
E		<u>ELC</u> <u>Eotaxin</u> <u>Eotaxin-2</u> <u>eotaxin-3</u> <u>ESkine</u> <u>Exodus-1</u> <u>Exodus-2</u> <u>Exodus-2</u>	<u>ECIP-1</u> <u>EDNAP</u> <u>ENA-78</u> <u>ENAP</u> <u>ENAP-alpha</u> <u>ENAP-beta</u> <u>Endothelial cell growth inhibitor</u> <u>Endothelial IL8</u>	
F		<u>FIC</u>	<u>FDNCF</u> <u>FINAP</u>	<u>Fractalkine</u>
G		<u>G26</u> <u>GDCF</u> <u>GDCF-2</u> <u>GOS-19-1</u> <u>GOS-19-2</u> <u>GOS-19-3</u>	<u>GCF</u> <u>GCP-2</u> <u>GRO1</u> <u>GRO2</u> <u>GRO3</u> <u>GRO-alpha</u> <u>GRO-beta</u> <u>GRO-gamma</u>	

H		<u>H400</u> <u>HC-11</u> <u>HC-14</u> <u>HC-21</u> <u>HCC-1</u> <u>HCC-2</u> <u>HCC-3</u> <u>HCC-4</u>	<u>H174</u> <u>Heparin neutralizing protein</u> <u>Humig</u>	
I		<u>I-309</u> <u>ILC</u> <u>ILINCK</u> <u>IMAC</u>	<u>I-TAC</u> <u>Ifi10</u> <u>IL8</u> <u>IP-9</u> <u>IP-10</u> <u>IRH</u>	
J		<u>JE</u>	<u>JSC</u>	
K		<u>K203</u>	<u>KC</u> <u>K60</u> <u>KEC</u> <u>KS1</u>	
L	<u>Lymphotactin</u>	<u>L2G25B</u> <u>LAG-1</u> <u>LARC</u> <u>LCC-1</u> <u>LD78-alpha</u> <u>LD78-beta</u> <u>LD78-gamma</u> <u>LDCF</u> <u>LEC</u> <u>Lkn-1</u> <u>LMC</u>	<u>LAI</u> <u>LCF</u> <u>LA-PF4</u> <u>LDGF</u> <u>LDNAP</u> <u>LIF</u> <u>LIX</u> <u>LUCT</u> <u>Lungkine</u> <u>LYNAP</u>	
M		<u>Manchester inhibitor</u> <u>MARC</u> <u>MCAF</u> <u>MCIF</u> <u>MCP-1</u> <u>MCP-2</u> <u>MCP-3</u> <u>MCP-4</u> <u>MCP-5</u> <u>MDC</u> <u>MEC</u> <u>MIP-1-alpha</u> <u>MIP-1-beta</u>	<u>M119</u> <u>MDGF</u> <u>MDNAP</u> <u>MDNCF</u> <u>Megakaryocyte-stimulatory-factor</u> <u>MGSA</u> <u>MGSA-alpha</u> <u>MGSA-beta</u> <u>Mig</u> <u>MIP-2</u> <u>MIP-2-alpha</u> <u>MIP-2-beta</u> <u>MIP-2-gamma</u>	

		<u>MIP-1-delta</u> <u>MIP-1-gamma</u> <u>MIP-3</u> <u>MIP-3-alpha</u> <u>MIP-3-beta</u> <u>MIP-4</u> <u>MIP-4-alpha</u> <u>MIP-5</u> <u>Monotactin-1</u> <u>MPIF-1</u> <u>MPIF-2</u> <u>MRP-1</u> <u>MRP-2</u> <u>Mtn-1</u>	<u>mob-1</u> <u>MOC</u> <u>MONAP</u>	
N		<u>NC28</u> <u>NCC-1</u> <u>NCC-2</u> <u>NCC-3</u> <u>NCC-4</u>	<u>N51</u> <u>NAF</u> <u>NAP-1</u> <u>NAP-2</u> <u>NAP-3</u> <u>NAP-4</u> <u>NAP S</u> <u>NCF</u> <u>NCP</u> <u>NJAC</u>	<u>Neurotactin</u>
O			<u>Oncostatin A</u>	
P		<u>P16</u> <u>P500</u> <u>PARC</u> <u>pAT464</u> <u>pAT744</u> <u>PESKY</u>	<u>PBP</u> <u>PBP-like</u> <u>PBSF</u> <u>PF4</u> <u>PF4-ALT</u> <u>PF4-ALT</u> <u>PF4V1</u> <u>PLF</u> <u>PPBP</u>	
R		<u>RANTES</u> <u>Regakine-1</u>		
S	<u>SCM-1-alpha</u> <u>SCYC1</u> <u>SCYC2</u>	<u>SCI</u> <u>SCYA1</u> <u>SCYA2</u> <u>SCYA3</u> <u>SCYA4</u> <u>SCYA5</u> <u>SCYA6</u> <u>SCYA7</u>	<u>SCYB1</u> <u>SCYB2</u> <u>SCYB3</u> <u>SCYB4</u> <u>SCYB5</u> <u>SCYB6</u> <u>SCYB7</u> <u>SCYB8</u>	<u>SCYD1</u> <u>SR-PSOX</u>

		<u>SCYA8</u> <u>SCYA9</u> <u>SCYA10</u> <u>SCYA11</u> <u>SCYA12</u> <u>SCYA13</u> <u>SCYA14</u> <u>SCYA15</u> <u>SCYA16</u> <u>SCYA17</u> <u>SCYA19</u> <u>SCYA20</u> <u>SCYA21</u> <u>SCYA22</u> <u>SCYA23</u> <u>SCYA24</u> <u>SCYA25</u> <u>SCYA26</u> <u>SCYA27</u> <u>SCYA28</u> <u>SIS-alpha</u> <u>SIS-beta</u> <u>SIS-delta</u> <u>SIS-epsilon</u> <u>SIS-gamma</u> <u>skinkine</u> <u>SLC</u> <u>SMC-CF</u> <u>ST38</u> <u>STCP-1</u>	<u>SCYB9</u> <u>SCYB9B</u> <u>SCYB10</u> <u>SCYB11</u> <u>SCYB12</u> <u>SCYB13</u> <u>SCYB14</u> <u>SCYB15</u> <u>SCYB16</u> <u>SDF-1-alpha</u> <u>SDF-1-beta</u> <u>SR-PSOX</u>	
T		<u>TARC</u> <u>TCA-3</u> <u>TCA-4</u> <u>TDCF</u> <u>TECK</u> <u>TSC-1</u> <u>TSG-8</u> <u>TY5</u>	<u>TCF</u> <u>TCK-1</u> <u>TLSF-alpha</u> <u>TLSF-beta</u> <u>TPAR-1</u> <u>TSG-1</u>	<u>trout</u> <u>chemokine 2</u>
W			<u>WECH</u>	
This alphabetical list of chemokines groups them into their respective families. Many of these factors have been described under different names and thus appear several times				

The biological activities of chemokines are mediated by specific receptors and

also by receptors with overlapping ligand specificities that bind several of these proteins which always belong either to the CC-Chemokines or the group of CXC-Chemokines. Lymphocytes require stimulation to become responsive to most known chemokines, and this process is linked closely to chemokine receptor expression. Chemokine receptors belong to the large group of G-protein-coupled seven transmembrane domain receptors which contain seven hydrophobic alpha-helical segments that transverse the membrane. These receptors form a structurally related group within the superfamily of G-protein-coupled receptors which mediate signaling via heterotrimeric G-proteins.

The receptors that bind CXC-Chemokines are designated **CXCR** followed by a number (see: **CXCR1**, **CXCR2**, **CXCR3**, **CXCR4**, **CXCR5**) while those binding CC-Chemokines are designated **CCR** followed by a number (see: **CCR1**, **CCR2**, **CCR3**, **CCR4**, **CCR5**, **CCR6**, **CCR7**, **CCR8**, **CCR9**, **CCR10**). For viral chemokine receptor homologs see also: ECRF-3, EBI-1 (EBV-induced gene-1), US28. For viral inhibitors of chemokine activities see also: vCCI, vCKBP. All chemokines have been shown to be capable of binding to heparin moieties of the extracellular matrix. Binding to heparan sulfate or heparin has been shown to enhance neutrophil responses to IL8.

Chemokines are essential mediators of normal leukocyte trafficking but their role is not restricted to cell attraction. Chemokines are multipotent cytokines that localize and enhance Inflammation by inducing chemotaxis and cell activation of different types of inflammatory cells typically present at inflammatory sites (see also: Motogenic cytokines). Chemokines and other mediators are secreted also by these cells. Most factors are induced and released into the circulation during acute infection but high concentrations of some chemokines are observed also in normal plasma.

Chemokines have been shown to exert their effects on distinct subsets of cells. CXC-Chemokines, for example appear to attract neutrophils but not macrophages, while CC-Chemokines preferentially induce migration of macrophages. Some chemokines have been shown to induce selective migration of leukocyte subsets.

It is now assumed that the combinatorial effects of multiple chemokines and other mediators are responsible for the cellular composition at inflammatory sites. In addition, many chemokines also directly cause cell activation. Some of them activate granulocytes and/or monocytes and cause respiratory bursts, degranulation, and the release of lysosomal enzymes. Others prime immune cells to respond to sub-optimal amounts of other inflammatory mediators (see also: Inflammation). Yet others have been shown to be potent histamine releasing factors for basophils. It has been proposed that erythrocytes through their promiscuous chemokine receptor play an important role in regulating the chemokine network. Chemokines bound to the erythrocyte receptor are known to be inaccessible to their normal target cells. This appears to provide a sink for superfluous chemokines and may serve to limit the systemic effects of these

mediators without disrupting localized processes taking place at the site of Inflammation .

Many genes encoding chemokines are expressed strongly during the course of a number of pathophysiological processes including autoimmune diseases, cancer, atherosclerosis, and chronic inflammatory diseases.

Certain CC-Chemokines exhibit biological activities other than mere chemotaxis . Some chemokines have been shown to be capable of inducing the proliferation and activation of killer cells known as CHAK (CC-Chemokine-activated killer), which are similar to cells activated by IL2 (see: LAK cells).

Some chemokines may have important developmental functions also apart from inducing Chemotaxis (see, for example: SDF). Several chemokines have been shown to modulate the growth of hematopoietic progenitor cell types and may thus have functions in hematopoiesis also (see, for example: BFU-E , CFU-GM , CFU-GEMM) and may play a role in trafficking of hematopoietic progenitor cells in and out of the bone marrow in inflammatory conditions. A number of additional functions of chemokines on angiogenesis , wound healing , tumor growth, metastasis, development, and genesis, homeostasis and function of the immune system have been reported also.

The importance of chemokines is underlined by the observation that chemokines and their receptors are especially important in the control of viral infection and replication. Some chemokines interfere with viral propagation by enhancing the cytotoxic activity of infected cells or by recruiting activated leukocytes to foci of infection to aid viral clearance. A medically important discovery is the observation that chemokines can suppress infection by HIV-1 and that chemokine receptors serve, along with CD4 , as obligate coreceptors for HIV-1 entry. Many viruses encode viral homologs of chemokines or chemokine binding proteins, termed virokine and viroceptor , respectively (see also: Virulence Factors MiniCOPE Dictionary).

For a strategy allowing manipulation of the cell surface expression of chemokine receptors that are involved in the pathogenesis of HIV virus infections (CCR5 and CXCR4) and thus also allowing a modification of cell susceptibility see also: intrakine .

date of last revision: March 2002

References: **Baggiolini M et al** Human chemokines: an update. Annual Review of Immunology 15: 675-705 (1997); **Jahnz-Rozyk K** Chemokines - New markers of inflammation. International Review of Allergology and Clinical Immunology 4(4): 143-149 (1998); **Luther SA and Cyster JG** Chemokines as regulators of T cell differentiation. Nature Immunology 2(2): 102-7 (2001); **Mackay CR** Chemokines: what chemokine is that? Current Biology 7(6): R384-386 (1997); **Mahalingam S et al** Antiviral potential of chemokines. Bioessays

23(5): 428-35 (2001); **Miller MD and Krangel MS** Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Critical Review of Immunology 12: 17-46 (1992); **Moser B et al** Lymphocyte responses to chemokines. International Review of Immunology 16(3-4): 323-344 (1998); **Moser B and Lentscher P** Lymphocyte traffic control by chemokines. Nature Immunology 2(2): 123-8 (2001); **Oppenheim JJ et al** Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annual Review of Immunology 9: 617-648 (1991); **Proudfoot AE et al** The strategy of blocking the chemokine system to combat disease. Immunological Reviews 177: 246-56 (2000); **Rossi D and Zlotnik A** The biology of chemokines and their receptors. Annual Reviews of Immunology 2000; 18:217-42 (2000); **Wang JM et al** Chemokines and their role in tumor growth and metastasis Journal of Immunological Methods 220(1-2): 1-17 (1998); **Yoshie O et al** Chemokines in immunity. Advances in Immunology 2001; 78: 57-110 (2001); **Zlotnik A et al** Recent advances in chemokines and chemokine receptors. Critical Reviews of Immunology 19(1): 1-47 (1999)

[A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#)
[Structure of COPE](#) | [Browse contents, new entries, subdictionaries](#)
[Awards, Recognition, and Server statistics](#)

Created, developed, and maintained by Horst Ibelgaufts
 Gene Center, Ludwig-Maximilians-Universität, München, Germany
[Contact information](#)

Copyright (C) 1997-2002 by Horst Ibelgaufts; supported by



cope.cgi version 0.014, revision April 8, 2002. (c) JI. Powered by Perl 5.00502

[Home](#)[Privacy Policy](#)[Contact Us/Questions](#)[Site Map](#)

SEARCH

enter keywords

[PRODUCTS](#)[OUR COMPANY](#)[INVESTOR RELATIONS](#)[INNOVATIONS](#)[NEWS](#)[IN THE COMMUN](#)

Error

Looking for Something?

The page you tried was not found. You may have used an outdated link or typed the address (URL) incorrectly. You might find what you're looking for these areas:

[Site Map](#)[Product Information](#)[Investor Information](#)[Careers](#)[Contact Information](#)[FAQ](#)


You can also try our search engine:

enter keywords

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our [Privacy Policy](#). Use of this site c your consent to application of such laws and regulations and to our [Privacy Policy](#). Your use of the information on this site is subj terms of our [Legal Notice](#). You should view the [News](#) section and the most recent SEC Filings in the [Investor Relations](#) section in receive the most current information made available by Johnson & Johnson. To [Contact Us](#) or search this site, please see the link of this page.

All contents © Copyright Johnson & Johnson 1997-2003. All Rights Reserved.

Last Updated: January 21, 2003

[Home](#)[Privacy Policy](#)[Contact Us/Questions](#)[Site Map](#)

SEARCH

CHF

A

[PRODUCTS](#)[OUR COMPANY](#)[INVESTOR RELATIONS](#)[INNOVATIONS](#)[NEWS](#)[IN THE COMMUNITY](#)

Search

SEARCH

☐ [Advanced Search](#)☐ [Search Hints](#)

Search Results

1



[Centocor Places Congestive Heart Failure Clinical Program On Hold \(05/06/Johnson & Johnson - News](#)

Malvern, PA (October 22, 2001) - Centocor, Inc., announced today that, for evaluation of the preliminary results of an ongoing Phase II clinical trial, for development of REMICADE® (infliximab) for the treatment of patients with c ... [More](#)



[2000 Contributions Annual Report \(PDF\) \(11/06/2002\)](#)

[Johnson & Johnson - In The Community](#)

2000 Worldwide Contributions Program Annual Report A Commitment to the Futures of Children Around the World The year 2000 provided all of us with opportunities and successes. Our worldwide contributions program continues and to ... [More](#)

Please select from the following search criteria.
Choosing more than one narrows your search.

Keyword:

CHF

Site Section:

jnj.com Only

Date Range:

All dates

Note: Date Range applies to jnj.com only, excluding the Investor Relations

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our [Privacy Policy](#). Use of this site constitutes your consent to application of such laws and regulations and to our [Privacy Policy](#). Your use of the information on this site is subject to the terms of our [Legal Notice](#). You should view the [News](#) section and the most recent SEC Filings in the [Investor Relations](#) section in order to receive the most current information made available by Johnson & Johnson. To [Contact Us](#) or search this site, please see the link at the bottom of this page.

All contents © Copyright Johnson & Johnson 1997-2003. All Rights Reserved.

Last Updated: January 21, 2003

.../search_results.htm?criteria=CHF&category=jnj&date_range=all&Sear1/28/2003


[Home](#)
[Privacy Policy](#)
[Contact Us/Questions](#)
[Site Map](#)

SEARCH

enter keywords

[PRODUCTS](#)
[OUR COMPANY](#)
[INVESTOR RELATIONS](#)
[INNOVATIONS](#)
[NEWS](#)
[IN THE COMMUNITY](#)

News



NEWS INDEX

- ☐ [Johnson & Johnson in the News](#)
- ☐ [News Archive](#)
- ☐ [Press Releases & Statements](#)

Note:

These press releases and statements were accurate, in all material respects, at the time of their issuance. However, Johnson & Johnson and the operating companies assume no obligation to update, correct or otherwise modify any of this material. We recommend that you view the most recent press releases and statements in order to receive the most current information made available by Johnson & Johnson.

[News / News Archive](#)

Centocor Places Congestive Heart Failure Clinical Program On Hold

Malvern, PA (October 22, 2001) - Centocor, Inc., announced today that, following evaluation of the preliminary results of an ongoing Phase II clinical trial, further development of REMICADE® (infliximab) for the treatment of patients with advanced congestive heart failure (CHF) has been placed on hold. The results demonstrated no improvement in patients' clinical status and showed higher incidence of mortality and hospitalization for worsening heart failure in patients treated with REMICADE®, especially those treated at the higher dose of 10 mg/kg.

This trial evaluated three infusions of REMICADE® 5 mg/kg, REMICADE® 10 mg/kg, or placebo over six weeks in patients with NYHA Class III-IV congestive heart failure. These patients typically experience either a marked limitation in, or a complete inability to, carry on any form of physical activity.

Over the next several weeks, Centocor will continue to follow patients who participated in the trial to better characterize the risks posed to patients with advanced CHF. In the interim, Centocor, in consultation with the U.S. Food and Drug Administration (FDA), has mailed a "Dear Doctor" letter communicating these preliminary results to health care professionals nationwide, and providing guidance on the management of patients receiving REMICADE® who have concomitant CHF. (A copy of this letter can be found at www.remicade.com.)

Although experimental preclinical studies and previous small clinical trials suggested that therapy targeted at tumor necrosis factor (TNF) might be of benefit in patients with CHF, this and other recent trials have failed to demonstrate that agents targeting TNF can improve the clinical course in these patients.

"Centocor is committed to ensuring that REMICADE® is used safely and effectively," said Jerry Boscia, M.D., vice president of clinical research and development. "More than 170,000 patients treated worldwide since its introduction in 1997, the benefit-to-risk ratio of REMICADE® is well established." He added that the company is fully committed to continuing its clinical development program for REMICADE® in other indications.

REMICADE® was the first biologic approved by the FDA for short-term use in patients with Crohn's disease who have had inadequate response to conventional therapy.

Archive

- ☐ [First Long-Term Wellness Program Confirms Employee Health Company Savings](#)
Johnson & Johnson (January 24, 2002)
- ☐ [Fourth Quarter Financial Results](#)
(January 22, 2002)
- ☐ [William C. Welton Succeeds Ralph J. Johnson as Chairman and CEO](#)
(January 22, 2002)
- ☐ [FDA Approves First DERMABOND® Seal Out Infectious Bacteria](#)
(January 16, 2002)
- ☐ [Johnson & Johnson Analysts Meeting Conference Call](#)
Quarter Earnings (January 16, 2002)
- ☐ [Biosense Webster New Soft-Tip Catheter Exceptional Market](#)
(January 15, 2002)
- ☐ [More News](#)

REMICADE® is also indicated, in combination with methotrexate, for reducing signs and symptoms and inhibiting progression of joint damage in patients moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate alone.

Centocor is a leading biopharmaceutical company that creates, acquires and develops cost-effective therapies that yield long-term benefits for patients and the healthcare community. Its products, developed primarily through monoclonal antibody technology, help physicians deliver innovative treatments to improve human health and restore patients' quality of life. Centocor is a wholly owned subsidiary of Johnson & Johnson, a worldwide leader in health care products. For more information on REMICADE® labeling, visit Centocor's Web site at www.centocor.com.

#

[Printer-friendly Version](#)

[TOP OF PAGE](#)

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our [Privacy Policy](#). Use of this site constitutes your consent to application of such laws and regulations and to our [Privacy Policy](#). Your use of the information on this site is subject to our [Legal Notice](#). You should view the [News](#) section and the most recent SEC Filings in the [Investor Relations](#) section in order to obtain the most current information made available by Johnson & Johnson. To [Contact Us](#) or search this site, please see the links at the top of the page. All contents © Copyright Johnson & Johnson 1997-2003. All Rights Reserved.

Last Updated: January 21, 2003

[Home](#)[Privacy Policy](#)[Contact Us/Questions](#)[Site Map](#)

SEARCH

[PRODUCTS](#)[OUR COMPANY](#)[INVESTOR RELATIONS](#)[INNOVATIONS](#)[NEWS](#)[IN THE COMMUN](#)

Error

Looking for Something?

The page you tried was not found. You may have used an outdated link or typed the address (URL) incorrectly. You might find what you're looking for these areas:

[Site Map](#)[Product Information](#)[Investor Information](#)[Careers](#)[Contact Information](#)[FAQ](#)

You can also try our search engine:

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our [Privacy Policy](#). Use of this site c your consent to application of such laws and regulations and to our [Privacy Policy](#). Your use of the information on this site is subj terms of our [Legal Notice](#). You should view the [News](#) section and the most recent SEC Filings in the [Investor Relations](#) section in receive the most current information made available by Johnson & Johnson. To [Contact Us](#) or search this site, please see the link of this page.

All contents © Copyright Johnson & Johnson 1997-2003. All Rights Reserved.

Last Updated: January 21, 2003


[Home](#)
[Privacy Policy](#)
[Contact Us/Questions](#)
[Site Map](#)

SEARCH

enter keywords

[PRODUCTS](#)
[OUR COMPANY](#)
[INVESTOR RELATIONS](#)
[INNOVATIONS](#)
[NEWS](#)
[IN THE COMMUNITY](#)

News



NEWS INDEX

- [Johnson & Johnson in the News](#)
- [News Archive](#)
- [Press Releases & Statements](#)

Note:

These press releases and statements were accurate, in all material respects, at the time of their issuance. However, Johnson & Johnson and the operating companies assume no obligation to update, correct or otherwise modify any of this material. We recommend that you view the most recent press releases and statements in order to receive the most current information made available by Johnson & Johnson.

[News / News Archive](#)

Centocor Places Congestive Heart Failure Clinical Program On Hold

Malvern, PA (October 22, 2001) – Centocor, Inc., announced today that, following evaluation of the preliminary results of an ongoing Phase II clinical trial, further development of REMICADE® (infliximab) for the treatment of patients with advanced congestive heart failure (CHF) has been placed on hold. The results demonstrated no improvement in patients' clinical status and showed higher incidence of mortality and hospitalization for worsening heart failure in patients treated with REMICADE®, especially those treated at the higher dose of 10 mg/kg.

This trial evaluated three infusions of REMICADE® 5 mg/kg, REMICADE® 10 mg/kg, or placebo over six weeks in patients with NYHA Class III-IV congestive heart failure. These patients typically experience either a marked limitation in, or a complete inability to, carry on any form of physical activity.

Over the next several weeks, Centocor will continue to follow patients who participated in the trial to better characterize the risks posed to patients with advanced CHF. In the interim, Centocor, in consultation with the U.S. Food and Drug Administration (FDA), has mailed a "Dear Doctor" letter communicating these preliminary results to health care professionals nationwide, and providing guidance on the management of patients receiving REMICADE® who have concomitant CHF. (A copy of this letter can be found at www.remicade.com.)

Although experimental preclinical studies and previous small clinical trials suggested that therapy targeted at tumor necrosis factor (TNF) might be of benefit in patients with CHF, this and other recent trials have failed to demonstrate that agents targeting TNF can improve the clinical course in these patients.

"Centocor is committed to ensuring that REMICADE® is used safely and effectively," said Jerry Boscia, M.D., vice president of clinical research and development. "We have treated more than 170,000 patients worldwide since its introduction in 1997, and the benefit-to-risk ratio of REMICADE® is well established." He added that the company is fully committed to continuing its clinical development program for REMICADE® in other indications.

REMICADE® was the first biologic approved by the FDA for short-term use in patients with Crohn's disease who have had inadequate response to conventional therapy.

Archive

- [First Long-Term Wellness Program Confirms Employee Health Company Savings](#) (January 24, 2002)
- [Fourth Quarter Financial Results](#) (January 22, 2002)
- [William C. Welton Succeeds Ralph J. Johnson as Chairman and CEO](#) (January 22, 2002)
- [FDA Approves L-lysine for the Treatment of DERMABOND® Seal Out Infectious Bacteria](#) (January 16, 2002)
- [Johnson & Johnson Analysts Meeting Conference Call](#) (January 16, 2002)
- [Biosense Webster Announces New Soft-Tip Catheter for Exceptional Mapping](#) (January 15, 2002)
- [More News](#)

REMICADE® is also indicated, in combination with methotrexate, for reducing signs and symptoms and inhibiting progression of joint damage in patients moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate alone.

Centocor is a leading biopharmaceutical company that creates, acquires and develops cost-effective therapies that yield long-term benefits for patients and the healthcare community. Its products, developed primarily through monoclonal antibody technology, help physicians deliver innovative treatments to improve human health and restore patients' quality of life. Centocor is a wholly owned subsidiary of Johnson & Johnson, a worldwide leader in health care products. For more information on REMICADE® labeling, visit Centocor's Web site at www.centocor.com.

#

[Printer-friendly Version](#)

[TOP OF PAGE](#)

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our [Privacy Policy](#). Use of this site constitutes your consent to application of such laws and regulations and to our [Privacy Policy](#). Your use of the information on this site is subject to our [Legal Notice](#). You should view the [News](#) section and the most recent SEC Filings in the [Investor Relations](#) section in order to obtain the most current information made available by Johnson & Johnson. To [Contact Us](#) or search this site, please see the links at the top of the page. All contents © Copyright Johnson & Johnson 1997-2003. All Rights Reserved.

Last Updated: January 21, 2003